ANGPT2 and macular retinal edema: The robust reduction in macular edema observed, potentially due to additional Ang-2 inhibition and improved vascular stability, underscores faricimab's potential to deliver consistent anatomical and functional improvements, particularly in nAMD patients with chronic fluid accumulation and poor response to prior anti-VEGF therapy.